BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
To determine the effect of low dose azacitidine therapy on tumor infiltrating lymphocytes
(TILs) in primary tumors from patients with high-risk early stage breast cancer, paired
t-tests will be first used to compare TIL count in pre- and post-treatment specimens.